Grant of Options

Oxford BioDynamics PLC

21 June 2024

 

                                                                      

 Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

PDMR Dealing / Grant of Share Options

21 June 2024 - Oxford BioDynamics Plc (AIM: OBD), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces that it has granted a total of 10,665,020 options over its ordinary shares of 1 pence each ("Ordinary Shares"), to certain Group employees, including 10,150,020 options to Chief Executive Officer, Dr Jon Burrows ("the Grant of Options"). The options were granted under the Company's 2016 Employee Share Option Plan with an exercise price of 9p per share.

One-third of the options granted to Dr Burrows will vest and become exercisable on each of 23 March 2025, 23 March 2026 and 23 March 2027. Vested options will remain exercisable up to and including the tenth anniversary of the date of grant.

Following this grant, Dr Jon Burrows, holds options over Ordinary Shares and is interested in Ordinary Shares as follows:

	Total number of options over Ordinary Shares	Ordinary Shares held
		Number	% of current issued share capital
Jon Burrows	12,773,734	1,088,888	0.35%

The Grant of Options constitutes a related party transaction pursuant to AIM Rule 13. The independent directors of the Company consider, having consulted with the Company's nominated adviser, Shore Capital and Corporate Limited, that the Grant of Options is fair and reasonable insofar as the Company's shareholders are concerned.

The information set out below is provided in accordance with the requirements of the UK Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Jon Burrows
2	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oxford BioDynamics Plc
b)	LEI	2138005Y1TK258O5U928
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 1 pence each ISIN:   GB00BD5H8572
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	10,150,020 Ordinary Shares at an exercise price of 9 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	21 June 2024
f)	Place of the transaction	Outside a trading venue

For further details please contact:

Oxford BioDynamics Plc Jon Burrows, CEO Paul Stockdale, CFO	Tel: [phone]
Shore Capital Nominated Adviser and Broker Stephane Auton / Lucy Bowden	Tel: [phone]
Instinctif Partners Melanie Toyne-Sewell / Katie Duffell / Jack Kincade	Tel: [phone] [e-mail]

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

It has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE is a blood test that boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer, which has been launched in the US and UK in September 2023. CiRT is a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

The Company's product portfolio is based on a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for the prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring, in a wide range of indications, including oncology, neurology, inflammation, hepatology and animal health.

In March 2021, the Company launched the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, the EpiSwitch Explorer Array Kit which is available for purchase by the life science research community. 

OBD has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 15,000 samples in more than 30 human diseases.

OBD's group headquarters and research, product development and UK clinical laboratories are in Oxford, UK. It also has a commercial office in Gaithersburg, MD, USA and a clinical laboratory in Frederick, MD, USA, and a reference laboratory in Penang, Malaysia.

The company is listed on the London Stock Exchange's AIM, with ticker OBD. For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow OBD on X (@OxBioDynamics) and LinkedIn.

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 15,000 samples in 30 disease areas, and reduced to practice.

In addition to stratifying patients with respect to anticipated clinical outcomes, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.

 

END